News
Current position:Product Center > Cell lines > Immunotherapy target > CD3 > CD3-CD2-tsAb Reporter Jurkat(CD58 KO) Cell Line
CD3-CD2-tsAb Reporter Jurkat(CD58 KO) Cell Line
Description
Cat. No: GM-C39956
Product: CD3-CD2-tsAb Reporter Jurkat(CD58 KO) Cell Line


CD3 is a core component of the T cell receptor (TCR) complex, while CD2 primarily mediates adhesion and costimulatory signaling; together, they enhance T cell responses.

PIT565, developed by Novartis, is a trispecific antibody that simultaneously binds CD3 and CD2 on T cells and CD19 on B cells; by recruiting and activating T cells to eliminate aberrant B cells, it shows promising potential in diseases characterized by B cell abnormalities, such as systemic lupus erythematosus and rheumatoid arthritis.

CD3-CD2-tsAb Reporter Jurkat(CD58 KO) Cell Line is a clonal stable Jurkat cell line constructed using non-viral vectors, knockout Endogenous CD58 gene, along with signal-dependent expression of a luciferase reporter gene. In this cell line, the reporter is expressed only when CD3 and CD2 pathways are activated, and the luciferase signal intensity directly reflects the magnitude of pathway activation. Therefore, this model provides a highly sensitive and specific platform for in vitro functional evaluation and mechanistic studies of CD3-CD2-tsAb trispecific antibodies.
Data
Response to Anti-CD19×CD3×CD2 hIgG1 Reference Antibody(PIT-565). H_CD19 CHO-K1 cells (Cat. GM-C19025) were seeded in 96-well plates at a density of 1E4 cells per well and incubated overnight. The next day, serial dilutions of the Anti-CD19×CD3×CD2 hIgG1 reference antibody (PIT-565) (Cat. GM-87914MAB) were prepared and added to each well together with 1E5 cells/well CD3-CD2-tsAb Reporter Jurkat(CD58 KO) Cell Line. The mixture was incubated for an additional 6 hours. Firefly luciferase activity was then measured using the GMOne-Step 2.0 Luciferase Reporter Gene Assay Kit (Cat. GM-040513). Data are shown by drug mass concentration.
Response to anti-human CD58 (LFA-3) Antibody. H_CD19 CHO-K1 cells (Cat. GM-C19025) were seeded at a density of 1E4 cells per well in a 96-well plate and incubated overnight. The next day, serial dilutions of the anti-human CD58 (LFA-3) antibody (BioLegend/330902) were incubated with 20 ng/well of Anti-CD19×CD3×CD2 (Cat. GM-87914MAB) for 1 hour. Then, together with the CD3-CD2-tsAb Reporter Jurkat (CD58 KO) Cell Line(Cat. GM-C39956), the mixture was added to the pre-seeded cells. The plates were further incubated for 6 hours. Firefly luciferase activity was then measured using the GMOne-Step 2.0 Luciferase Reporter Gene Assay Kit (Cat. GM-040513). The results indicated a maximum blocking fold of approximately 6.3. Data are shown as a function of drug mass concentration.
CD3-CD2-tsAb Reporter Jurkat(CD58 KO) Cell Line(Cat. GM-C39956) was determined by flow cytometry using Purified anti-human CD58 (LFA-3) Antibody (Biolegend/330902).
Jurkat Cell Line was determined by flow cytometry using anti-CD3 hIgG1 Antibody(CH2527) (Cat. GM-33037AB).
Jurkat Cell Line was determined by flow cytometry using Anti-CD2 hIgG1 Antibody(BTI-322) (Cat. GM-79929AB).
Specifications
Cat. NoGM-C39956
ProductCD3-CD2-tsAb Reporter Jurkat(CD58 KO) Cell Line
Product Format1 vial of frozen cells
Quantity5E6 Cells per vial,1 mL
Storage ConditionsLiquid nitrogen immediately upon receipt
Recovery MediumRPMI 1640+10% FBS+1% P.S
Growth mediumRPMI 1640+10% FBS+1% P.S+3.5 μg/mL Blasticidin
NoteNone
Freezing Medium90% FBS+10% DMSO
Growth propertiesSuspension
Growth Conditions37°C, 5% CO₂
Safety considerationsJurkat cells are classified as BSL-1 by ATCC and BSL-2 by ECACC, constructed using non-viral vectors; please choose appropriate biosafety measures according to local regulations.
Mycoplasma TestingThe cell line has been screened to confirm the absence of Mycoplasma species.
Materials
ReagentOrdering Information
RPMI 1640gibco/C11875500BT
Fetal Bovine SerumExCell/FSP500
Pen/StrepThermo/15140-122
BlasticidinGenomeditech/GM-040404
H_CD19 CHO-K1 Cell lineGenomeditech/GM-C19025
Anti-CD19×CD3×CD2 hIgG1 Reference Antibody(PIT-565)Genomeditech/GM-87914MAB
Purified anti-human CD58 (LFA-3) AntibodyBiolegend/330902
Anti-CD3 hIgG1 Antibody(CH2527)Genomeditech/GM-33037AB
Anti-CD2 hIgG1 Antibody(BTI-322)Genomeditech/GM-79929AB
GMOne-Step 2.0 Luciferase Reporter Gene Assay KitGenomeditech/GM-040513
Cell Culture

Cell Recovery

Recovery Medium: RPMI 1640+10% FBS+1% P.S

To insure the highest level of viability, thaw the vial and initiate the culture as soon as possible upon receipt. If upon arrival, continued storage of the frozen culture is necessary, it should be stored in liquid nitrogen vapor phase and not at -70°C. Storage at -70°C will result in loss of viability.

a)       Thaw the vial by gentle agitation in a 37°C water bath. To reduce the possibility of contamination, keep the O-ring and cap out of the water. Thawing should be rapid (approximately 2 - 3 minutes).

b)       Remove the vial from the water bath as soon as the contents are thawed, and decontaminate by dipping in or spraying with 70% ethanol. All of the operations from this point on should be carried out under strict aseptic conditions.

c)       Transfer the vial contents to a centrifuge tube containing 5.0 mL complete culture medium. And spin at approximately 176 x g for 5 minutes. Discard supernatant.

d)       Resuspend cell pellet with the recommended complete medium. And dispense the suspension into 1 - 2 T-25 culture flasks.

e)       Incubate the culture at 37°C in a suitable incubator. A 5% CO₂ in air atmosphere is recommended if using the medium described on this product sheet.

Cell Freezing

Freezing Medium: 90% FBS+10% DMSO

a)          Centrifuge at 176 x g for 3 minutes to collect cells.

b)         Resuspend the cells in pre-cooled freezing medium and adjust the cell density to 5E6 cells/mL.

c)          Aliquot 1 mL into each vial.

d)         Place the vial in a controlled-rate freezing container and store at -80°C for at least 1 day, then transfer to liquid nitrogen as soon as possible.

Cell passage

Growth medium: RPMI 1640+10% FBS+1% P.S+3.5 μg/mL Blasticidin

Approximately 48-72 hours after the initial thawing, the cells can be passaged for the first time. After this initial passage, the culture medium can be adjusted to growth medium supplemented with antibiotics. If cells are not passaged within 48 hours, it is recommended to add some fresh recovery medium and place the flask horizontally.

a)          When the cell density reaches 1.5 - 2E6 cells/mL, subculture the cells. Do not allow the cell density to exceed 2E6 cells/mL.

b)         It is recommended to use T-25 flasks for subculturing.

c)          These cells are suspension cells, and it is recommended to use the "half-medium change" method to maintain optimal cell conditions during passaging.

d)         During passaging, you can directly add fresh growth medium to the culture flask, gently pipette to resuspend the cells, and then transfer the cell suspension to a new T-25 flask for continued culture.

Subcultivation Ratio: Maintain cultures at a cell concentraion between 3E5 and 1E6 viable cells/mL.

Medium Renewal: Every 2 to 3 days

Notes

a)          These cells are sensitive to density, so please ensure that the cell density is maintained within an appropriate range during culture and subculturing.

b)         During the first passage, pay attention to the nutrient supply; if not subculturing, make sure to add fresh recovery medium every other day as needed.


Message Consultation
If you have more questions, please fill in the relevant information,we'll respond as soon as possible to assist you!
Reset
Submit
You can also contact us on the Scientist and Science Exchange marketplaces.
Current Position:Product Center > Cell lines > Immunotherapy target > CD3 > CD3-CD2-tsAb Reporter Jurkat(CD58 KO) Cell Line
classify
CD3-CD2-tsAb Reporter Jurkat(CD58 KO) Cell Line
Description
Cat. No: GM-C39956
Product: CD3-CD2-tsAb Reporter Jurkat(CD58 KO) Cell Line


CD3 is a core component of the T cell receptor (TCR) complex, while CD2 primarily mediates adhesion and costimulatory signaling; together, they enhance T cell responses.

PIT565, developed by Novartis, is a trispecific antibody that simultaneously binds CD3 and CD2 on T cells and CD19 on B cells; by recruiting and activating T cells to eliminate aberrant B cells, it shows promising potential in diseases characterized by B cell abnormalities, such as systemic lupus erythematosus and rheumatoid arthritis.

CD3-CD2-tsAb Reporter Jurkat(CD58 KO) Cell Line is a clonal stable Jurkat cell line constructed using non-viral vectors, knockout Endogenous CD58 gene, along with signal-dependent expression of a luciferase reporter gene. In this cell line, the reporter is expressed only when CD3 and CD2 pathways are activated, and the luciferase signal intensity directly reflects the magnitude of pathway activation. Therefore, this model provides a highly sensitive and specific platform for in vitro functional evaluation and mechanistic studies of CD3-CD2-tsAb trispecific antibodies.
Data
Response to Anti-CD19×CD3×CD2 hIgG1 Reference Antibody(PIT-565). H_CD19 CHO-K1 cells (Cat. GM-C19025) were seeded in 96-well plates at a density of 1E4 cells per well and incubated overnight. The next day, serial dilutions of the Anti-CD19×CD3×CD2 hIgG1 reference antibody (PIT-565) (Cat. GM-87914MAB) were prepared and added to each well together with 1E5 cells/well CD3-CD2-tsAb Reporter Jurkat(CD58 KO) Cell Line. The mixture was incubated for an additional 6 hours. Firefly luciferase activity was then measured using the GMOne-Step 2.0 Luciferase Reporter Gene Assay Kit (Cat. GM-040513). Data are shown by drug mass concentration.
Response to anti-human CD58 (LFA-3) Antibody. H_CD19 CHO-K1 cells (Cat. GM-C19025) were seeded at a density of 1E4 cells per well in a 96-well plate and incubated overnight. The next day, serial dilutions of the anti-human CD58 (LFA-3) antibody (BioLegend/330902) were incubated with 20 ng/well of Anti-CD19×CD3×CD2 (Cat. GM-87914MAB) for 1 hour. Then, together with the CD3-CD2-tsAb Reporter Jurkat (CD58 KO) Cell Line(Cat. GM-C39956), the mixture was added to the pre-seeded cells. The plates were further incubated for 6 hours. Firefly luciferase activity was then measured using the GMOne-Step 2.0 Luciferase Reporter Gene Assay Kit (Cat. GM-040513). The results indicated a maximum blocking fold of approximately 6.3. Data are shown as a function of drug mass concentration.
CD3-CD2-tsAb Reporter Jurkat(CD58 KO) Cell Line(Cat. GM-C39956) was determined by flow cytometry using Purified anti-human CD58 (LFA-3) Antibody (Biolegend/330902).
Jurkat Cell Line was determined by flow cytometry using anti-CD3 hIgG1 Antibody(CH2527) (Cat. GM-33037AB).
Jurkat Cell Line was determined by flow cytometry using Anti-CD2 hIgG1 Antibody(BTI-322) (Cat. GM-79929AB).
Specifications
Cat. NoGM-C39956
ProductCD3-CD2-tsAb Reporter Jurkat(CD58 KO) Cell Line
Product Format1 vial of frozen cells
Quantity5E6 Cells per vial,1 mL
Storage ConditionsLiquid nitrogen immediately upon receipt
Recovery MediumRPMI 1640+10% FBS+1% P.S
Growth mediumRPMI 1640+10% FBS+1% P.S+3.5 μg/mL Blasticidin
NoteNone
Freezing Medium90% FBS+10% DMSO
Growth propertiesSuspension
Growth Conditions37°C, 5% CO₂
Safety considerationsJurkat cells are classified as BSL-1 by ATCC and BSL-2 by ECACC, constructed using non-viral vectors; please choose appropriate biosafety measures according to local regulations.
Mycoplasma TestingThe cell line has been screened to confirm the absence of Mycoplasma species.
Materials
ReagentOrdering Information
RPMI 1640gibco/C11875500BT
Fetal Bovine SerumExCell/FSP500
Pen/StrepThermo/15140-122
BlasticidinGenomeditech/GM-040404
H_CD19 CHO-K1 Cell lineGenomeditech/GM-C19025
Anti-CD19×CD3×CD2 hIgG1 Reference Antibody(PIT-565)Genomeditech/GM-87914MAB
Purified anti-human CD58 (LFA-3) AntibodyBiolegend/330902
Anti-CD3 hIgG1 Antibody(CH2527)Genomeditech/GM-33037AB
Anti-CD2 hIgG1 Antibody(BTI-322)Genomeditech/GM-79929AB
GMOne-Step 2.0 Luciferase Reporter Gene Assay KitGenomeditech/GM-040513
Cell Culture

Cell Recovery

Recovery Medium: RPMI 1640+10% FBS+1% P.S

To insure the highest level of viability, thaw the vial and initiate the culture as soon as possible upon receipt. If upon arrival, continued storage of the frozen culture is necessary, it should be stored in liquid nitrogen vapor phase and not at -70°C. Storage at -70°C will result in loss of viability.

a)       Thaw the vial by gentle agitation in a 37°C water bath. To reduce the possibility of contamination, keep the O-ring and cap out of the water. Thawing should be rapid (approximately 2 - 3 minutes).

b)       Remove the vial from the water bath as soon as the contents are thawed, and decontaminate by dipping in or spraying with 70% ethanol. All of the operations from this point on should be carried out under strict aseptic conditions.

c)       Transfer the vial contents to a centrifuge tube containing 5.0 mL complete culture medium. And spin at approximately 176 x g for 5 minutes. Discard supernatant.

d)       Resuspend cell pellet with the recommended complete medium. And dispense the suspension into 1 - 2 T-25 culture flasks.

e)       Incubate the culture at 37°C in a suitable incubator. A 5% CO₂ in air atmosphere is recommended if using the medium described on this product sheet.

Cell Freezing

Freezing Medium: 90% FBS+10% DMSO

a)          Centrifuge at 176 x g for 3 minutes to collect cells.

b)         Resuspend the cells in pre-cooled freezing medium and adjust the cell density to 5E6 cells/mL.

c)          Aliquot 1 mL into each vial.

d)         Place the vial in a controlled-rate freezing container and store at -80°C for at least 1 day, then transfer to liquid nitrogen as soon as possible.

Cell passage

Growth medium: RPMI 1640+10% FBS+1% P.S+3.5 μg/mL Blasticidin

Approximately 48-72 hours after the initial thawing, the cells can be passaged for the first time. After this initial passage, the culture medium can be adjusted to growth medium supplemented with antibiotics. If cells are not passaged within 48 hours, it is recommended to add some fresh recovery medium and place the flask horizontally.

a)          When the cell density reaches 1.5 - 2E6 cells/mL, subculture the cells. Do not allow the cell density to exceed 2E6 cells/mL.

b)         It is recommended to use T-25 flasks for subculturing.

c)          These cells are suspension cells, and it is recommended to use the "half-medium change" method to maintain optimal cell conditions during passaging.

d)         During passaging, you can directly add fresh growth medium to the culture flask, gently pipette to resuspend the cells, and then transfer the cell suspension to a new T-25 flask for continued culture.

Subcultivation Ratio: Maintain cultures at a cell concentraion between 3E5 and 1E6 viable cells/mL.

Medium Renewal: Every 2 to 3 days

Notes

a)          These cells are sensitive to density, so please ensure that the cell density is maintained within an appropriate range during culture and subculturing.

b)         During the first passage, pay attention to the nutrient supply; if not subculturing, make sure to add fresh recovery medium every other day as needed.


Message Consultation
If you have more questions, please fill in the relevant information,we'll respond as soon as possible to assist you!
Reset
Submit
You can also contact us on the Scientist and Science Exchange marketplaces.
Message consultation
reset
submit
Service
Message
Message consultation
reset
submit